Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.71 |
| ▸ | PLA2G2A | P14555 | 15/20 | 0.56 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11824093 | 0.92 | HTR6 (0.70) | HTR6PLA2G2APLA2G1B | |
| SCHEMBL11827008 | 0.91 | HTR6 (0.69) | HTR6PLA2G2APLA2G1B | |
| Hydrochloric Acid SCHEMBL11827022 | 0.91 | HTR6 (0.69) | HTR6PLA2G2APLA2G1B | |
| SCHEMBL6699386 | 0.90 | HTR6 (0.67) | HTR6PLA2G2A | |
| SCHEMBL11826210 | 0.89 | HTR6 (0.64) | HTR6PLA2G2A | |
| SCHEMBL11826084 | 0.89 | HTR6 (0.66) | HTR6PLA2G2APLA2G1B | |
| SCHEMBL5764974 | 0.89 | HTR6 (0.72) | HTR6PLA2G2APLA2G1B | |
| SCHEMBL11834372 | 0.87 | HTR6 (0.64) | HTR6PLA2G2APLA2G1B | |
| SCHEMBL6984962 | 0.87 | HTR6 (0.61) | HTR6PLA2G2A | |
| SCHEMBL29862561 | 0.86 | PLA2G2A (0.59) | HTR6PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110825-A1 | Administration of an enzyme inhibitor of human non-pancreatic scretory phospholipase A2 (sPLA2) if activity levels are high or on the rise; treating within 0-24 hours after first organ failure and continuing as necessary, i.e., 1-7 days | LOH ANDREW (US) | 2004-06-10 | — | — | US | disclosed |
| EP-0839806-B1 | Substituted tricyclics | LILLY CO ELI (US) | 2003-07-09 | — | — | EP | disclosed |
| EP-1303262-A2 | USE OF A SPLA2 INHIBITOR FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002005796-A2 | USE OF A SPLA2 INHIBITOR FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
| EP-0839806-A1 | Substituted tricyclics | ELI LILLY AND COMPANY (US) | 1998-05-06 | — | — | EP | disclosed |
| US-3979391-A | 1,2,3,4-Tetrahydrocarbazoles | STERLING DRUG INC. (US) | 1976-09-07 | — | — | US | disclosed |
| US-3939177-A | 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles | STERLING DRUG INC. (US) | 1976-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110825-A1 | Administration of an enzyme inhibitor of human non-pancreatic scretory phospholipase A2 (sPLA2) if activity levels are high or on the rise; treating within 0-24 hours after first organ failure and continuing as necessary, i.e., 1-7 days | PLA2G12A, PLA2G2E, PLA2G3 | HTR6 3251/4885PLA2G2A 24/4885PLA2G1B 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.